DESTINY-Breast Guide: 1795TiP at #ESMO26 🌍
In triple-positive mBC, can we do DB-09 induction and PATINA maintenance?
DB-09 made T-DXd + pertuzumab a 1L option. PATINA showed palbociclib + ET + HP maintenance improves PFS after induction (HR 0.75). DB-Guide puts them together.
How long to induce? In a DB-09 post hoc analysis, median time to maximal tumor reduction was ~11 mo (~16 cycles) overall and ~13 mo (~19 cycles) in HER2+/HR+ disease. A 6-cycle stop (~4 mo) lands well before most patients hit their best response.
DESTINY-Breast Guide (N=200, single-arm): 1️⃣ T-DXd + pertuzumab for 18-24 cycles (12m), or switch after 8 cycles with confirmed CR 2️⃣ Palbociclib + ET + HP maintenance 3️⃣ T-DXd retreatment at progression.
Primary endpoint: 24-mo PFS. QOL built in.
Recruiting in the US, Canada, Europe, China, Korea, and Australia, and coming soon to @UMGCCC
#BCSM #HER2 #ADC #BreastCancer
51 views · 1 like · 0 reposts · 0 replies
Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgSource: Dr Sarah Sammons · x.com